2018
A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaSerous ovarian carcinomaIL-6Ovarian cancerOvarian carcinomaE-cadHigh-grade serous ovarian adenocarcinomaEarly-stage ovarian cancerROC analysisEarly detectionMajority of patientsLethal gynecologic malignancyStage ovarian cancerOvarian cancer patientsBenign gynecologic pathologyNon-cancer controlsSerous ovarian adenocarcinomaEffective cancer screeningSerous ovarian cancerMultiple biomarker panelsFour-marker panelHigh differential gene expressionGynecologic malignanciesCA 125IL-1ra
2009
Human Kallikrein 5
Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, Tognon G, Ragnoli M, Santin AD, Gion M, Pecorelli S, Ravaggi A. Human Kallikrein 5. International Journal Of Gynecological Cancer 2009, 19: 1015-1021. PMID: 19820362, DOI: 10.1111/igc.0b013e3181ab597f.Peer-Reviewed Original ResearchConceptsOvarian carcinomaBorderline tumorsHealthy controlsPathological lesionsKLK5 levelsSpontaneous humoral immune responseBenign pathological lesionsImmune-based therapiesOvarian borderline tumorsSera of patientsHumoral immune responseBenign pelvic massesOvarian cancer progressionPotential new biomarkersEnzyme-linked immunosorbentOvarian cancer detectionHealthy womenPelvic massHumoral responseAntibody responseObstetricians stageImmune responsePatientsNew biomarkersCarcinoma